GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spruce Biosciences Inc (NAS:SPRB) » Definitions » Book Value per Share

Spruce Biosciences (Spruce Biosciences) Book Value per Share : $1.62 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Spruce Biosciences Book Value per Share?

Spruce Biosciences's book value per share for the quarter that ended in Mar. 2024 was $1.62.

During the past 12 months, Spruce Biosciences's average Book Value Per Share Growth Rate was -40.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -33.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Spruce Biosciences was -33.80% per year. The lowest was -33.80% per year. And the median was -33.80% per year.

Spruce Biosciences's current price is $0.7699. Its book value per share for the quarter that ended in Mar. 2024 was $1.62. Hence, today's PB Ratio of Spruce Biosciences is 0.48.

During the past 6 years, the highest P/B Ratio of Spruce Biosciences was 2.94. The lowest was 0.39. And the median was 0.86.


Spruce Biosciences Book Value per Share Historical Data

The historical data trend for Spruce Biosciences's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spruce Biosciences Book Value per Share Chart

Spruce Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial -3.35 6.42 4.74 2.90 1.87

Spruce Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.72 2.37 2.10 1.87 1.62

Competitive Comparison of Spruce Biosciences's Book Value per Share

For the Biotechnology subindustry, Spruce Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spruce Biosciences's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spruce Biosciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Spruce Biosciences's PB Ratio falls into.



Spruce Biosciences Book Value per Share Calculation

Spruce Biosciences's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(76.51-0.00)/41.03
=1.86

Spruce Biosciences's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(66.62-0.00)/41.15
=1.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Spruce Biosciences  (NAS:SPRB) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Spruce Biosciences Book Value per Share Related Terms

Thank you for viewing the detailed overview of Spruce Biosciences's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Spruce Biosciences (Spruce Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
Executives
Percival Barretto-ko director 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO CA 94080
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Niall O'donnell director C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Charlton Ralph William Iii officer: Chief Medical Officer 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94104
Javier B. Szwarcberg director, officer: Chief Executive Officer 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94014
Kirk Ways director C/O 2001 JUNIPERO SERRA BOULEVARD, SUITE 540, DALY CITY CA 94014
Camilla V Simpson director 20 ELAINE AVE., MILL VALLEY CA 94941
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Jonas Hansson director 18 AVENUE D'OUCHY, LAUSANNE V8 CH-1006
Rivervest Venture Fund Iii (ohio), L.p. 10 percent owner 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Healthcap Viii, L.p. 10 percent owner 18 AVENUE D'OUCHY, C/O HEALTHCAP VIII GP SA, CH 1006 LAUSANNE V8 1006
Moghrabi Dina Chaya director 22 GLEDHOW GARDENS, FLAT 2, LONDON X0 SW5 0AZ
Omega Fund Vi Gp Manager, Ltd. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Samir M. Gharib officer: Chief Financial Officer 2655 PINE STREET, #6, SAN FRANCISCO CA 94115
Richard King director, officer: Chief Executive Officer C/O KOS PHARMACEUTICALS INC, 1001 BRICKELL AVE 25TH FL, MIAMI FL 33131